引用本文:高 丹(综述),陶 洁(审校).B细胞受体信号通路抑制剂治疗慢性淋巴细胞白血病的研究进展[J].中国临床新医学,2018,11(12):1269-1272.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 318次   下载 121 本文二维码信息
码上扫一扫!
分享到: 微信 更多
B细胞受体信号通路抑制剂治疗慢性淋巴细胞白血病的研究进展
高 丹(综述),陶 洁(审校)
030001 太原,山西医科大学(高 丹);030001 太原,山西医科大学第一医院(陶 洁)
摘要:
[摘要] 慢性淋巴细胞白血病(chronic lymphocytic leukemia,CLL)是西方国家最常见的B细胞恶性肿瘤之一。我国虽然缺乏确切的流行病学数据,但随着人口老龄化及诊断水平的提高,CLL发病率有逐年增长趋势。其特征是成熟B淋巴细胞在骨髓、淋巴结、血液、脾脏、肝脏及其他器官聚集。经传统免疫化疗后,部分CLL患者可获得长期无进展生存(progression-free survival,PFS),但对于复发/难治、存在高危细胞遗传学等因素的患者其预后仍较差。近年来层出不穷的新型药物可改善此类患者的预后。该文就依鲁替尼、idelalisib两种B细胞受体(B-cell receptor,BCR)信号通路抑制剂在CLL中应用的临床研究进展作一综述。
关键词:  慢性淋巴细胞白血病  B细胞受体信号通路抑制剂  依鲁替尼  idelalisib
DOI:10.3969/j.issn.1674-3806.2018.12.28
分类号:R 733.72
基金项目:
Research progress of B-cell receptor signaling pathway inhibitors in treatment of chronic lymphocytic leukemia
GAO Dan, TAO Jie
Shanxi Medical University, Taiyuan 030001, China
Abstract:
[Abstract] Chronic lymphocytic leukemia(CLL) is one of the most common B cell malignancies in western countries. Despite the lack of accurate epidemiological data in China, the incidence of CLL is increasing with aging of population and the improvement of diagnostic level. It is characterized by the accumulation of mature B lymphocytes in bone marrow, lymph nodes, blood, spleen, liver and other organs. Long-term progression-free survival(PFS) can be achieved in some CLL patients after traditional immunochemotherapy, but the prognosis of the patients with recurrent/refractory and high risk cytogenetics is still unfavourable. The emerging new drugs in recent years can improve the prognosis of these patients. The research progress of two B-cell receptor signaling pathway inhibitors, ibrutinib and idelalisib, in treatment of CLL is reviewed in this paper.
Key words:  Chronic lymphocytic leukemia(CLL)  B-cell receptor signaling pathway inhibitors  Ibrutinib  Idelalisib